# US 2022/0010389 A1 · Primer set for detecting sars-cov-2, method for testing sars-cov-2, and reagent and kit of testing sars-cov-2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0010389 A1
- Document ID: US20220010389A1
- Status: Published application
- Kind: A1
- Application number: 17/489,049
- Filed: 2021-09-29
- Published: 2022-01-13
- Earliest claimed: 2020-06-15
- Assignees: Nagasaki University
- Applicants: Nagasaki University; Canon Medical Systems Corporation
- Inventors: Jiro YASUDA; Rokusuke YOSHIKAWA; Haruka ABE
- Web page: https://patentgrep.com/patent/US20220010389A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

One embodiment according to the present invention relates to a primer set for detecting SARS-CoV-2, the set comprising a plurality of LAMP primers targeting one or more open reading frame (ORF) regions in a SARS-CoV-2 genome, wherein the one or more ORF regions are selected from the group consisting of Orf1b, OrfM, OrfN, and OrfS; and a technique relating to use of this primer set.

## Claims

### Claim 1

A primer set for detecting SARS-CoV-2, the primer set comprising a plurality of LAMP primers targeting one or more open reading frame (ORF) regions in a SARS-CoV-2 genome,
wherein the primer set comprises one or more primer sets selected from the group consisting of the following (1) to (4):
(1) a primer set comprising four primers comprising the nucleotide sequences of SEQ ID NOs:13-16 or the nucleotide sequences complementary thereto, respectively;
(2) a primer set comprising four primers comprising the nucleotide sequences of SEQ ID NOs:19-22 or the nucleotide sequences complementary thereto, respectively;
(3) a primer set comprising four primers comprising the nucleotide sequences of SEQ ID NOs:25-28 or the nucleotide sequences complementary thereto, respectively; and
(4) a primer set comprising four primers comprising the nucleotide sequences of SEQ ID NOs:43-46 or the nucleotide sequences complementary thereto, respectively.

### Claim 2 (depends on 1)

The primer set according to claim 1, wherein the primer set comprises the primer set of either (1) or (2) or the primer sets of both (1) and (2).

### Claim 3 (depends on 1)

The primer set according to claim 1, wherein the primer set comprises the primer set of (1).

### Claim 4 (depends on 1)

A method for testing SARS-CoV-2, the method comprising detecting SARS-CoV-2 in a specimen obtained from a subject by using the primer set according to claim 1 in an RT-LAMP method.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the specimen is nasal swab, pharyngeal swab, saliva, or sputum.

### Claim 6 (depends on 4)

The method according to claim 4, wherein SARS-CoV-2 is detected after heating the specimen.

### Claim 7 (depends on 1)

A reagent of testing SARS-CoV-2, comprising the primer set according to any one of claims 1.

### Claim 8 (depends on 1)

A kit of testing SARS-CoV-2, comprising the following (1) to (3):
(1) the primer set according to claims 1;
(2) a strand-displacement DNA polymerase; and
(3) a reverse transcriptase.

### Claim 9

A primer set for detecting SARS-CoV-2, the primer set comprising a plurality of LAMP primers targeting one or more open reading frame (ORF) regions in a SARS-CoV-2 genome,
wherein the primer set comprises one or more primer sets selected from the group consisting of the following (1) to (4):
(1) a primer set comprising six primers comprising the nucleotide sequences of SEQ ID NOs:13-18 or the nucleotide sequences complementary thereto, respectively;
(2) a primer set comprising six primers comprising the nucleotide sequences of SEQ ID NOs:19-24 or the nucleotide sequences complementary thereto, respectively;
(3) a primer set comprising six primers comprising the nucleotide sequences of SEQ ID NOs:25-30 or the nucleotide sequences complementary thereto, respectively; and
(4) a primer set comprising six primers comprising the nucleotide sequences of SEQ ID NOs:43-48 or the nucleotide sequences complementary thereto, respectively.

### Claim 10 (depends on 9)

The primer set according to claim 9, wherein the primer set comprises the primer set of either (1) or (2) or the primer sets of both (1) and (2).

### Claim 11 (depends on 9)

The primer set according to claim 9, wherein the primer set comprises the primer set of (1).

### Claim 12 (depends on 9)

A method for testing SARS-CoV-2, the method comprising detecting SARS-CoV-2 in a specimen obtained from a subject by using the primer set according to claim 9 in an RT-LAMP method.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the specimen is nasal swab, pharyngeal swab, saliva, or sputum.

### Claim 14 (depends on 12)

The method according to claim 12, wherein SARS-CoV-2 is detected after heating the specimen.

### Claim 15 (depends on 9)

A reagent of testing SARS-CoV-2, comprising the primer set according to claim 9.

### Claim 16 (depends on 9)

A kit of testing SARS-CoV-2, comprising the following (1) to (3):
(1) the primer set according to claim 9;
(2) a strand-displacement DNA polymerase; and
(3) a reverse transcriptase.
